Oncotarget

Research Papers:

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma

Xuefei Sun, Jing Liu, Yaming Wang, Xueyan Bai, Yuedan Chen, Jun Qian, Hong Zhu, Fusheng Liu, Xiaoguang Qiu, Shengjun Sun, Nan Ji and Yuanbo Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49156-49164. https://doi.org/10.18632/oncotarget.17101

Metrics: PDF 1023 views  |   HTML 1747 views  |   ?  


Abstract

Xuefei Sun1,*, Jing Liu1,*, Yaming Wang2, Xueyan Bai1, Yuedan Chen1, Jun Qian1, Hong Zhu1, Fusheng Liu3, Xiaoguang Qiu4, Shengjun Sun5, Nan Ji6 and Yuanbo Liu1

1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

2Department of Neurosurgery, Navy General Hospital, Beijing, China

3Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

4Department of Radiation Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

5Neuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

6Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

*These authors contributed equally to this work

Correspondence to:

Yuanbo Liu, email: yuanbol@ccmu.edu.cn

Keywords: primary central nervous system lymphoma, rituximab, high-dose methotrexate, cytarabine, survival

Received: December 21, 2016     Accepted: April 02, 2017     Published: April 13, 2017

ABSTRACT

Purpose: High-dose methotrexate based chemotherapy is the standard treatment for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of rituximab is controversial because of its large size, which limits its penetration of the blood-brain barrier. In this study, we investigated the efficacy and tolerability of adding rituximab to methotrexate-cytarabine-dexamethasone combination therapy (RMAD regimen).

Results: The patients treated with RMAD had a complete remission rate of 66.7% after induction chemotherapy; this rate was only 33.3% in patients treated with MAD alone (p = .011). The most common grade 1–3 adverse events were similar and included hematologic toxicity, increased aminotransferase levels, and gastrointestinal reactions. Multivariate analysis revealed that rituximab treatment was associated with longer progression-free survival (PFS, p = .005) but not overall survival (OS). Additionally, we observed that elevated serum lactate dehydrogenase was associated with shorter OS and PFS.

Materials and Methods: We retrospectively analyzed 60 immunocompetent patients with newly diagnosed PCNSL at Beijing Tiantan Hospital, Capital Medical University from January 2010 to June 2016. Twenty-four patients received 3–6 courses of 3.5 g/m2 methotrexate on day 1; 0.5–1 g/m2 cytarabine on day 2; and 5–10 mg dexamethasone on days 1, 2 and 3. Thirty-six patients received the same combination plus rituximab 375 mg/m2 on day 0. All patients repeated the treatment every 3 weeks.

Conclusions: High-dose methotrexate based chemotherapy with rituximab yields a higher complete remission rate and does not increase serious toxicities. PFS benefits from the addition of rituximab. OS has an increasing trend in patients treated with rituximab without statistical significance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17101